drugset / Trial / NCT05311475

Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis

NCT05311475

Phase 3 Completed 669 enrolled Sandoz
RandomizedParallel-groupDouble-blindTreatment

Summary

The trial will be conducted as a prospective, randomized, multinational, multicenter, double-blind, placebo and active controlled trial in 4 parallel-groups of patients suffering from seasonal allergic rhinitis.

Timeline

Start
2022-04-04
Primary completion
2023-06-20
Completion
2023-06-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Azelastine Small molecule 140 ug Intranasal
Subject Mometasone Other / unclassified 50 ug Intranasal